

July 20, 2023

National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001

Symbol: LALPATHLAB

Scrip Code: 539524

## Sub: Notice of Board Meeting

## Ref: Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

This is to inform you that a meeting of the Board of Directors is scheduled to be held on Thursday, July 27, 2023 to inter-alia consider and approve the Un-audited (Standalone & Consolidated) Financial Results of the Company for the Quarter ended June 30, 2023 and to consider the proposal of declaration of interim dividend, if any, on the equity shares of the Company for the Financial Year 2023-24.

Further, in continuation to our letter dated June 30, 2023 and in line with the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company's code for Prevention of Insider Trading, the Trading Window for dealing in Securities of the Company is closed and shall re-open after 48 hours from the declaration of the aforesaid Financial Results.

We request you to kindly take the same on record.

Thanking You, Yours Faithfully,

## For Dr. Lal PathLabs Limited

## Vinay Gujral Company Secretary & Compliance Officer

Regd. Office: Dr. Lal PathLabs Ltd., Block E, Sector-18, Rohini, New Delhi - 110085, C +91-11-30258600, Fax: +91-11-2788-2134 Corporate Office: Dr. Lal PathLabs Ltd., 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurugram - 122 001, Haryana +91-124-3016-500, Fax: +91-124-4234-468 E-mail: lalpathlabs.com, Web: www.lalpathlabs.com, CIN No.: L74899DL1995PLC065388